Home Mid-Atlantic Yardley, PA Savara Pharmaceuticals COMPANY
Clinical Phase 3
2 open jobs · last seen Oct 23, 2026 · 10 sources
Keywords: respiratory inhaled immunology pulmonary alveolar proteinosis Autoimmune Pulmonary Alveolar Proteinosis Cystic Fibrosis Nontuberculous Mycobacterium Infections Bronchiectasis Acute Respiratory Distress Syndrome Molgramostim Show all 10 keywords
Location: Yardley, PA · source · Oct 15, 2026
Profile checked Oct 10, 2026
At a glance HQ Yardley, PA source Region Mid-Atlantic Stage Clinical Phase 3 Latest trial Phase 3: Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). (Oct 22, 2025) source Timeline Oct 22, 2025 Trial start Phase 3: Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). source ↗ May 19, 2021 Trial start Phase 3: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) source ↗ Jun 20, 2019 Trial start Phase 2: Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection source ↗ Apr 16, 2018 Trial start Phase 3: Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis source ↗ Mar 1, 2018 Trial start Phase 2: Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection source ↗ Sep 20, 2017 Trial start Phase 3: AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis source ↗ Mar 21, 2016 Trial start Phase 2: Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis source ↗ 2015-05 Trial start Phase 1: Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects source ↗ 2013-03 Trial start Phase 2: Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients source ↗ 2011-11 Trial start Phase 1: Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics source ↗ Upcoming milestones 2027-06 (ESTIMATED) · Phase 3 · Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). · NCT06431776 Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 11 Record Title Phase Status Start Primary completion NCT04544293 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Phase 3 Active, not recruiting May 19, 2021 Nov 30, 2023 (actual) NCT06546098 Molgramostim Nebulizer Solution Expanded Access Program Protocol Not listed Available Not listed Not listed NCT06431776 Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Phase 3 Recruiting Oct 22, 2025 2027-06 (estimated) NCT03421743 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection Phase 2 Completed Mar 1, 2018 Oct 15, 2019 (actual) NCT03482752 Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Phase 3 Terminated Apr 16, 2018 Jan 14, 2021 (actual) NCT02702180 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Phase 2 Completed Mar 21, 2016 Apr 19, 2019 (actual) NCT03597347 Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Phase 2 Terminated Jun 20, 2019 Oct 2, 2020 (actual) NCT03181932 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis Phase 3 Completed Sep 20, 2017 Jul 28, 2020 (actual) NCT01746095 Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients Phase 2 Completed 2013-03 2014-11 (actual) NCT02468908 Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects Phase 1 Completed 2015-05 2015-10 (actual) NCT01537666 Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics Phase 1 Completed 2011-11 2012-03 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗ Open jobs 2 Title Location (from posting, not HQ) Employer posted First seen Level Patient Access Manager (PAM) - NW/Rockies (Denver, SLC, Seattle) PA, US Oct 20, 2026 Oct 22, 2026 Not stated Consultant, Clinical Quality Assurance and Early Access Programs PA, US Sep 8, 2026 Oct 11, 2026 Mid Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
